Our Technologies

Cambridge Epigenetix is pioneering the field of clinical epigenetics. Using our technology, researchers have proven the link between the epigenetic DNA modification 5-hydroxymethylcytosine (5hmC) and disease. This is now one of the most important biomarkers in the quest to improve human health.

    Disruptive epigenetics discovery platform to improve human health

    Technologies

    Innovative technologies based on our fundamental chemistry and scientific expertise

    Our disruptive epigenetics discovery platform enables the identification of sensitive and disease-specific epigenetic marks from blood and tissue samples — enhancing human health through earlier diagnosis, improved patient stratification and the development of liquid biopsy-based tests.

    The Power of Epigenetics

    The power of 5-hydoxymethylcytosine (5hmC)

    Research has revealed a wide range of diagnostic and prognostic applications for 5hmC:

    • Earlier disease detection
    • Identification of tissue of origin
    • Robust detection from liquid biopsy samples
    • Identification of new therapeutic targets
    Learn More
    Learn More

    5-hydroxymethylcytosine pull-down (HMCP)

    PROPRIETARY TECHNOLOGIES

    HMCP delivers highly-sensitive and specific detection of 5hmC from circulating cell-free DNA (cfDNA) and other clinical sample types. This platform technology powers our in-house diagnostic development programmes.

    Cambridge Epigenetix is now offering an HMCP biomarker discovery service to select partners as part of our Early Access Program. If you are interested in enrolling, please contact us for more details.

    Minimally invasive sample collection enables repeat testing and improves patient compliance

    No more than a standard blood draw required for discovery and clinical assay

    Robust and automatable workflow that can scale for clinical biomarker discovery and diagnostic applications

    Can reveal information on cell and disease states that cannot be determined by genetic analysis

    Learn more

    Oxidative bisulfite sequencing (oxBS-Seq)

    PROPRIETARY TECHNOLOGIES

    Our founding technology, TrueMethyl oxidative bisulfite sequencing (oxBS-Seq) revolutionised the field of epigenetics – allowing researchers to accurately sequence 5mC and 5hmC at single-base resolution for the first time. Professor Shankar Balasubramanian and Dr Michael Booth invented and first published oxBS-Seq in 2012 and it is now the new gold standard for bisulfite sequencing. Discover how researchers are using oxBS to further elucidate the role of 5hmC.

    Distinguishes between 5hmC and 5mC

    Single-base resolution method for 5hmC and 5mC quantification

    Compatible with a large range of DNA methylation methods

    Streamlined data analysis workflow

    Cambridge Epigenetix retains the rights for diagnostic use of oxBS-Seq; however, researchers can access this technology through our partnership with NuGEN Technologies, Inc.

    Visit NuGEN

    Find out more

    For more information about our proprietary technologies, get in touch.

    Request more information